nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—FYN—stomach cancer	0.25	0.512	CbGaD
Bosutinib—CHEK2—stomach cancer	0.17	0.348	CbGaD
Bosutinib—EGFR—stomach cancer	0.0678	0.139	CbGaD
Bosutinib—EGFR—Docetaxel—stomach cancer	0.0434	0.604	CbGbCtD
Bosutinib—ABCB1—Mitomycin—stomach cancer	0.0137	0.191	CbGbCtD
Bosutinib—ABCB1—Irinotecan—stomach cancer	0.00352	0.0491	CbGbCtD
Bosutinib—ABCB1—Docetaxel—stomach cancer	0.00258	0.036	CbGbCtD
Bosutinib—CYP3A4—Irinotecan—stomach cancer	0.00211	0.0294	CbGbCtD
Bosutinib—ABCB1—Doxorubicin—stomach cancer	0.00193	0.0268	CbGbCtD
Bosutinib—ABCB1—Methotrexate—stomach cancer	0.00187	0.026	CbGbCtD
Bosutinib—CYP3A4—Docetaxel—stomach cancer	0.00155	0.0215	CbGbCtD
Bosutinib—Vandetanib—FYN—stomach cancer	0.00153	0.375	CrCbGaD
Bosutinib—CYP3A4—Doxorubicin—stomach cancer	0.00115	0.0161	CbGbCtD
Bosutinib—Gefitinib—CHEK2—stomach cancer	0.000989	0.242	CrCbGaD
Bosutinib—WEE1—Paclitaxel—Docetaxel—stomach cancer	0.000866	0.243	CbGdCrCtD
Bosutinib—CDK2—Paclitaxel—Docetaxel—stomach cancer	0.000706	0.198	CbGdCrCtD
Bosutinib—Vandetanib—VEGFA—stomach cancer	0.000493	0.121	CrCbGaD
Bosutinib—Vandetanib—EGFR—stomach cancer	0.000416	0.102	CrCbGaD
Bosutinib—Gefitinib—EGFR—stomach cancer	0.000395	0.0968	CrCbGaD
Bosutinib—ABL1—Topotecan—Irinotecan—stomach cancer	0.000294	0.0826	CbGdCrCtD
Bosutinib—WEE1—Daunorubicin—Epirubicin—stomach cancer	0.00029	0.0814	CbGdCrCtD
Bosutinib—WEE1—Daunorubicin—Doxorubicin—stomach cancer	0.000268	0.0753	CbGdCrCtD
Bosutinib—CHEK2—Paclitaxel—Docetaxel—stomach cancer	0.000216	0.0608	CbGdCrCtD
Bosutinib—ERBB3—digestive system—stomach cancer	0.000198	0.00165	CbGeAlD
Bosutinib—STK36—endocrine gland—stomach cancer	0.000198	0.00165	CbGeAlD
Bosutinib—ULK3—digestive system—stomach cancer	0.000198	0.00165	CbGeAlD
Bosutinib—MAP2K2—digestive system—stomach cancer	0.000198	0.00165	CbGeAlD
Bosutinib—LRRK2—bone marrow—stomach cancer	0.000197	0.00165	CbGeAlD
Bosutinib—MAP4K5—pancreas—stomach cancer	0.000196	0.00164	CbGeAlD
Bosutinib—YES1—smooth muscle tissue—stomach cancer	0.000196	0.00163	CbGeAlD
Bosutinib—BTK—liver—stomach cancer	0.000196	0.00163	CbGeAlD
Bosutinib—MERTK—endocrine gland—stomach cancer	0.000196	0.00163	CbGeAlD
Bosutinib—SRC—epithelium—stomach cancer	0.000195	0.00163	CbGeAlD
Bosutinib—SYK—lymph node—stomach cancer	0.000195	0.00163	CbGeAlD
Bosutinib—TNIK—lymph node—stomach cancer	0.000195	0.00163	CbGeAlD
Bosutinib—TBK1—lymphoid tissue—stomach cancer	0.000194	0.00162	CbGeAlD
Bosutinib—PTK2—lymphoid tissue—stomach cancer	0.000194	0.00162	CbGeAlD
Bosutinib—CDK2—lymph node—stomach cancer	0.000193	0.00161	CbGeAlD
Bosutinib—TNK2—liver—stomach cancer	0.000193	0.00161	CbGeAlD
Bosutinib—PTK2B—bone marrow—stomach cancer	0.000192	0.00161	CbGeAlD
Bosutinib—PTK2—digestive system—stomach cancer	0.000192	0.0016	CbGeAlD
Bosutinib—TBK1—digestive system—stomach cancer	0.000192	0.0016	CbGeAlD
Bosutinib—MAP4K4—endocrine gland—stomach cancer	0.000192	0.0016	CbGeAlD
Bosutinib—CSF1R—hematopoietic system—stomach cancer	0.000192	0.0016	CbGeAlD
Bosutinib—STK26—lymph node—stomach cancer	0.000191	0.0016	CbGeAlD
Bosutinib—BCR—endocrine gland—stomach cancer	0.000191	0.00159	CbGeAlD
Bosutinib—MAP4K2—liver—stomach cancer	0.00019	0.00159	CbGeAlD
Bosutinib—MAP3K12—endocrine gland—stomach cancer	0.000189	0.00158	CbGeAlD
Bosutinib—SRC—smooth muscle tissue—stomach cancer	0.000188	0.00157	CbGeAlD
Bosutinib—STK3—liver—stomach cancer	0.000188	0.00157	CbGeAlD
Bosutinib—RPS6KB1—lymphoid tissue—stomach cancer	0.000187	0.00156	CbGeAlD
Bosutinib—SIK1—bone marrow—stomach cancer	0.000186	0.00156	CbGeAlD
Bosutinib—IRAK4—bone marrow—stomach cancer	0.000186	0.00156	CbGeAlD
Bosutinib—FGR—lymphoid tissue—stomach cancer	0.000186	0.00155	CbGeAlD
Bosutinib—STK35—endocrine gland—stomach cancer	0.000185	0.00155	CbGeAlD
Bosutinib—MAP2K1—endocrine gland—stomach cancer	0.000185	0.00155	CbGeAlD
Bosutinib—AXL—lymphoid tissue—stomach cancer	0.000185	0.00155	CbGeAlD
Bosutinib—ROCK1—liver—stomach cancer	0.000185	0.00155	CbGeAlD
Bosutinib—CHEK2—lymph node—stomach cancer	0.000185	0.00154	CbGeAlD
Bosutinib—RPS6KB1—digestive system—stomach cancer	0.000185	0.00154	CbGeAlD
Bosutinib—CSK—endocrine gland—stomach cancer	0.000184	0.00154	CbGeAlD
Bosutinib—FGR—digestive system—stomach cancer	0.000184	0.00153	CbGeAlD
Bosutinib—DMPK—lymph node—stomach cancer	0.000183	0.00153	CbGeAlD
Bosutinib—WEE1—lymph node—stomach cancer	0.000183	0.00153	CbGeAlD
Bosutinib—CSNK1A1—endocrine gland—stomach cancer	0.000183	0.00153	CbGeAlD
Bosutinib—ULK3—bone marrow—stomach cancer	0.000182	0.00152	CbGeAlD
Bosutinib—MAP2K2—bone marrow—stomach cancer	0.000182	0.00152	CbGeAlD
Bosutinib—CLK1—endocrine gland—stomach cancer	0.000182	0.00152	CbGeAlD
Bosutinib—HCK—endocrine gland—stomach cancer	0.000182	0.00152	CbGeAlD
Bosutinib—YES1—pancreas—stomach cancer	0.000181	0.00151	CbGeAlD
Bosutinib—MAP3K2—bone marrow—stomach cancer	0.000181	0.00151	CbGeAlD
Bosutinib—BMPR2—liver—stomach cancer	0.00018	0.0015	CbGeAlD
Bosutinib—MAP3K7—bone marrow—stomach cancer	0.000179	0.0015	CbGeAlD
Bosutinib—TAOK3—pancreas—stomach cancer	0.000179	0.00149	CbGeAlD
Bosutinib—CAMK2G—endocrine gland—stomach cancer	0.000178	0.00149	CbGeAlD
Bosutinib—BMP2K—endocrine gland—stomach cancer	0.000178	0.00149	CbGeAlD
Bosutinib—STK36—liver—stomach cancer	0.000178	0.00149	CbGeAlD
Bosutinib—TBK1—bone marrow—stomach cancer	0.000177	0.00148	CbGeAlD
Bosutinib—LRRK2—endocrine gland—stomach cancer	0.000177	0.00148	CbGeAlD
Bosutinib—MERTK—liver—stomach cancer	0.000176	0.00147	CbGeAlD
Bosutinib—STK25—lymph node—stomach cancer	0.000175	0.00146	CbGeAlD
Bosutinib—EPHB4—digestive system—stomach cancer	0.000175	0.00146	CbGeAlD
Bosutinib—SRC—pancreas—stomach cancer	0.000174	0.00145	CbGeAlD
Bosutinib—EPHA3—lymph node—stomach cancer	0.000174	0.00145	CbGeAlD
Bosutinib—EPHA2—lymphoid tissue—stomach cancer	0.000174	0.00145	CbGeAlD
Bosutinib—IRAK1—bone marrow—stomach cancer	0.000174	0.00145	CbGeAlD
Bosutinib—FYN—lymphoid tissue—stomach cancer	0.000173	0.00145	CbGeAlD
Bosutinib—MAP4K4—liver—stomach cancer	0.000173	0.00145	CbGeAlD
Bosutinib—PTK2B—endocrine gland—stomach cancer	0.000172	0.00144	CbGeAlD
Bosutinib—BCR—liver—stomach cancer	0.000172	0.00144	CbGeAlD
Bosutinib—NUAK2—liver—stomach cancer	0.000172	0.00144	CbGeAlD
Bosutinib—EPHA2—digestive system—stomach cancer	0.000172	0.00143	CbGeAlD
Bosutinib—FYN—digestive system—stomach cancer	0.000171	0.00143	CbGeAlD
Bosutinib—MAP3K12—liver—stomach cancer	0.000171	0.00143	CbGeAlD
Bosutinib—RPS6KB1—bone marrow—stomach cancer	0.00017	0.00142	CbGeAlD
Bosutinib—PLK2—lymph node—stomach cancer	0.00017	0.00142	CbGeAlD
Bosutinib—PDGFRB—hematopoietic system—stomach cancer	0.00017	0.00142	CbGeAlD
Bosutinib—CSNK1E—endocrine gland—stomach cancer	0.00017	0.00142	CbGeAlD
Bosutinib—MAP4K5—lymphoid tissue—stomach cancer	0.000169	0.00141	CbGeAlD
Bosutinib—FGR—bone marrow—stomach cancer	0.000169	0.00141	CbGeAlD
Bosutinib—LCK—bone marrow—stomach cancer	0.000169	0.00141	CbGeAlD
Bosutinib—SIK3—lymph node—stomach cancer	0.000169	0.00141	CbGeAlD
Bosutinib—CSF1R—smooth muscle tissue—stomach cancer	0.000169	0.00141	CbGeAlD
Bosutinib—MAP2K1—liver—stomach cancer	0.000167	0.0014	CbGeAlD
Bosutinib—STK35—liver—stomach cancer	0.000167	0.0014	CbGeAlD
Bosutinib—SIK1—endocrine gland—stomach cancer	0.000167	0.00139	CbGeAlD
Bosutinib—CSK—liver—stomach cancer	0.000166	0.00139	CbGeAlD
Bosutinib—EPHA4—endocrine gland—stomach cancer	0.000165	0.00138	CbGeAlD
Bosutinib—CSNK1A1—liver—stomach cancer	0.000165	0.00138	CbGeAlD
Bosutinib—HCK—liver—stomach cancer	0.000164	0.00137	CbGeAlD
Bosutinib—CLK1—liver—stomach cancer	0.000164	0.00137	CbGeAlD
Bosutinib—ERBB3—endocrine gland—stomach cancer	0.000164	0.00137	CbGeAlD
Bosutinib—MAP2K2—endocrine gland—stomach cancer	0.000163	0.00136	CbGeAlD
Bosutinib—ULK3—endocrine gland—stomach cancer	0.000163	0.00136	CbGeAlD
Bosutinib—ABL2—liver—stomach cancer	0.000163	0.00136	CbGeAlD
Bosutinib—STK4—lymph node—stomach cancer	0.000163	0.00136	CbGeAlD
Bosutinib—SLK—bone marrow—stomach cancer	0.000162	0.00136	CbGeAlD
Bosutinib—MAP3K2—endocrine gland—stomach cancer	0.000162	0.00135	CbGeAlD
Bosutinib—EPHB4—bone marrow—stomach cancer	0.000161	0.00135	CbGeAlD
Bosutinib—CAMK2G—liver—stomach cancer	0.000161	0.00134	CbGeAlD
Bosutinib—BMP2K—liver—stomach cancer	0.000161	0.00134	CbGeAlD
Bosutinib—CAMK1D—lymph node—stomach cancer	0.000161	0.00134	CbGeAlD
Bosutinib—LRRK2—liver—stomach cancer	0.000159	0.00133	CbGeAlD
Bosutinib—STK24—lymph node—stomach cancer	0.000159	0.00133	CbGeAlD
Bosutinib—EGFR—liver—stomach cancer	0.000159	0.00133	CbGeAlD
Bosutinib—PTK2—endocrine gland—stomach cancer	0.000159	0.00133	CbGeAlD
Bosutinib—TBK1—endocrine gland—stomach cancer	0.000159	0.00133	CbGeAlD
Bosutinib—FYN—bone marrow—stomach cancer	0.000158	0.00132	CbGeAlD
Bosutinib—YES1—lymphoid tissue—stomach cancer	0.000156	0.00131	CbGeAlD
Bosutinib—PDGFRB—epithelium—stomach cancer	0.000156	0.0013	CbGeAlD
Bosutinib—PTK2B—liver—stomach cancer	0.000155	0.0013	CbGeAlD
Bosutinib—STK10—lymphoid tissue—stomach cancer	0.000155	0.00129	CbGeAlD
Bosutinib—YES1—digestive system—stomach cancer	0.000155	0.00129	CbGeAlD
Bosutinib—TAOK3—lymphoid tissue—stomach cancer	0.000154	0.00129	CbGeAlD
Bosutinib—MAP4K5—bone marrow—stomach cancer	0.000154	0.00129	CbGeAlD
Bosutinib—MAP3K3—bone marrow—stomach cancer	0.000154	0.00129	CbGeAlD
Bosutinib—ALK—lymph node—stomach cancer	0.000154	0.00128	CbGeAlD
Bosutinib—FER—lymph node—stomach cancer	0.000154	0.00128	CbGeAlD
Bosutinib—STK10—digestive system—stomach cancer	0.000153	0.00128	CbGeAlD
Bosutinib—CSNK1E—liver—stomach cancer	0.000153	0.00128	CbGeAlD
Bosutinib—RPS6KB1—endocrine gland—stomach cancer	0.000153	0.00128	CbGeAlD
Bosutinib—TAOK3—digestive system—stomach cancer	0.000153	0.00127	CbGeAlD
Bosutinib—FGR—endocrine gland—stomach cancer	0.000152	0.00127	CbGeAlD
Bosutinib—ABL1—hematopoietic system—stomach cancer	0.000152	0.00127	CbGeAlD
Bosutinib—AXL—endocrine gland—stomach cancer	0.000151	0.00126	CbGeAlD
Bosutinib—MAP4K1—lymph node—stomach cancer	0.000151	0.00126	CbGeAlD
Bosutinib—SIK1—liver—stomach cancer	0.000151	0.00126	CbGeAlD
Bosutinib—IRAK4—liver—stomach cancer	0.000151	0.00126	CbGeAlD
Bosutinib—SRC—lymphoid tissue—stomach cancer	0.00015	0.00126	CbGeAlD
Bosutinib—BTK—lymph node—stomach cancer	0.00015	0.00125	CbGeAlD
Bosutinib—PDGFRB—smooth muscle tissue—stomach cancer	0.00015	0.00125	CbGeAlD
Bosutinib—SRC—digestive system—stomach cancer	0.000149	0.00124	CbGeAlD
Bosutinib—TNK2—lymph node—stomach cancer	0.000148	0.00123	CbGeAlD
Bosutinib—ERBB3—liver—stomach cancer	0.000148	0.00123	CbGeAlD
Bosutinib—MAP2K2—liver—stomach cancer	0.000147	0.00123	CbGeAlD
Bosutinib—ULK3—liver—stomach cancer	0.000147	0.00123	CbGeAlD
Bosutinib—MAP3K2—liver—stomach cancer	0.000146	0.00122	CbGeAlD
Bosutinib—MAP4K2—lymph node—stomach cancer	0.000146	0.00122	CbGeAlD
Bosutinib—MAP3K7—liver—stomach cancer	0.000145	0.00121	CbGeAlD
Bosutinib—EPHB4—endocrine gland—stomach cancer	0.000144	0.00121	CbGeAlD
Bosutinib—STK3—lymph node—stomach cancer	0.000144	0.0012	CbGeAlD
Bosutinib—PTK2—liver—stomach cancer	0.000143	0.0012	CbGeAlD
Bosutinib—TBK1—liver—stomach cancer	0.000143	0.0012	CbGeAlD
Bosutinib—YES1—bone marrow—stomach cancer	0.000142	0.00119	CbGeAlD
Bosutinib—EPHA2—endocrine gland—stomach cancer	0.000142	0.00118	CbGeAlD
Bosutinib—FYN—endocrine gland—stomach cancer	0.000141	0.00118	CbGeAlD
Bosutinib—STK10—bone marrow—stomach cancer	0.000141	0.00118	CbGeAlD
Bosutinib—TAOK3—bone marrow—stomach cancer	0.000141	0.00117	CbGeAlD
Bosutinib—IRAK1—liver—stomach cancer	0.00014	0.00117	CbGeAlD
Bosutinib—PDGFRB—pancreas—stomach cancer	0.000139	0.00116	CbGeAlD
Bosutinib—MAP4K5—endocrine gland—stomach cancer	0.000138	0.00115	CbGeAlD
Bosutinib—MAP3K3—endocrine gland—stomach cancer	0.000138	0.00115	CbGeAlD
Bosutinib—BMPR2—lymph node—stomach cancer	0.000138	0.00115	CbGeAlD
Bosutinib—RPS6KB1—liver—stomach cancer	0.000138	0.00115	CbGeAlD
Bosutinib—LCK—liver—stomach cancer	0.000137	0.00114	CbGeAlD
Bosutinib—FGR—liver—stomach cancer	0.000137	0.00114	CbGeAlD
Bosutinib—STK36—lymph node—stomach cancer	0.000137	0.00114	CbGeAlD
Bosutinib—EPHB3—lymph node—stomach cancer	0.000137	0.00114	CbGeAlD
Bosutinib—AXL—liver—stomach cancer	0.000136	0.00114	CbGeAlD
Bosutinib—MERTK—lymph node—stomach cancer	0.000135	0.00113	CbGeAlD
Bosutinib—CSF1R—lymphoid tissue—stomach cancer	0.000135	0.00113	CbGeAlD
Bosutinib—ABL1—smooth muscle tissue—stomach cancer	0.000134	0.00112	CbGeAlD
Bosutinib—CSF1R—digestive system—stomach cancer	0.000133	0.00111	CbGeAlD
Bosutinib—MAP4K4—lymph node—stomach cancer	0.000133	0.00111	CbGeAlD
Bosutinib—Vandetanib—ALB—stomach cancer	0.000133	0.0324	CrCbGaD
Bosutinib—BCR—lymph node—stomach cancer	0.000132	0.0011	CbGeAlD
Bosutinib—NUAK2—lymph node—stomach cancer	0.000132	0.0011	CbGeAlD
Bosutinib—SLK—liver—stomach cancer	0.000131	0.0011	CbGeAlD
Bosutinib—MAP3K12—lymph node—stomach cancer	0.000131	0.00109	CbGeAlD
Bosutinib—EPHB4—liver—stomach cancer	0.00013	0.00109	CbGeAlD
Bosutinib—MAP2K1—lymph node—stomach cancer	0.000128	0.00107	CbGeAlD
Bosutinib—STK35—lymph node—stomach cancer	0.000128	0.00107	CbGeAlD
Bosutinib—EPHA2—liver—stomach cancer	0.000128	0.00107	CbGeAlD
Bosutinib—YES1—endocrine gland—stomach cancer	0.000128	0.00107	CbGeAlD
Bosutinib—FYN—liver—stomach cancer	0.000128	0.00107	CbGeAlD
Bosutinib—CSK—lymph node—stomach cancer	0.000127	0.00106	CbGeAlD
Bosutinib—STK10—endocrine gland—stomach cancer	0.000127	0.00106	CbGeAlD
Bosutinib—CSNK1A1—lymph node—stomach cancer	0.000127	0.00106	CbGeAlD
Bosutinib—TAOK3—endocrine gland—stomach cancer	0.000126	0.00105	CbGeAlD
Bosutinib—Gefitinib—ALB—stomach cancer	0.000126	0.0308	CrCbGaD
Bosutinib—HCK—lymph node—stomach cancer	0.000126	0.00105	CbGeAlD
Bosutinib—CLK1—lymph node—stomach cancer	0.000126	0.00105	CbGeAlD
Bosutinib—ABL2—lymph node—stomach cancer	0.000125	0.00104	CbGeAlD
Bosutinib—MAP4K5—liver—stomach cancer	0.000125	0.00104	CbGeAlD
Bosutinib—MAP3K3—liver—stomach cancer	0.000125	0.00104	CbGeAlD
Bosutinib—ABL1—pancreas—stomach cancer	0.000124	0.00103	CbGeAlD
Bosutinib—BMP2K—lymph node—stomach cancer	0.000123	0.00103	CbGeAlD
Bosutinib—CAMK2G—lymph node—stomach cancer	0.000123	0.00103	CbGeAlD
Bosutinib—CSF1R—bone marrow—stomach cancer	0.000123	0.00103	CbGeAlD
Bosutinib—SRC—endocrine gland—stomach cancer	0.000123	0.00103	CbGeAlD
Bosutinib—LRRK2—lymph node—stomach cancer	0.000122	0.00102	CbGeAlD
Bosutinib—EGFR—lymph node—stomach cancer	0.000122	0.00102	CbGeAlD
Bosutinib—PDGFRB—lymphoid tissue—stomach cancer	0.00012	0.001	CbGeAlD
Bosutinib—PTK2B—lymph node—stomach cancer	0.000119	0.000995	CbGeAlD
Bosutinib—PDGFRB—digestive system—stomach cancer	0.000118	0.000988	CbGeAlD
Bosutinib—CSNK1E—lymph node—stomach cancer	0.000117	0.000979	CbGeAlD
Bosutinib—SIK1—lymph node—stomach cancer	0.000115	0.000964	CbGeAlD
Bosutinib—IRAK4—lymph node—stomach cancer	0.000115	0.000964	CbGeAlD
Bosutinib—YES1—liver—stomach cancer	0.000115	0.000961	CbGeAlD
Bosutinib—EPHA4—lymph node—stomach cancer	0.000114	0.000954	CbGeAlD
Bosutinib—STK10—liver—stomach cancer	0.000114	0.000953	CbGeAlD
Bosutinib—TAOK3—liver—stomach cancer	0.000114	0.000949	CbGeAlD
Bosutinib—ERBB3—lymph node—stomach cancer	0.000113	0.000945	CbGeAlD
Bosutinib—MAP2K5—endocrine gland—stomach cancer	0.000113	0.000944	CbGeAlD
Bosutinib—ULK3—lymph node—stomach cancer	0.000113	0.000942	CbGeAlD
Bosutinib—MAP2K2—lymph node—stomach cancer	0.000113	0.000942	CbGeAlD
Bosutinib—MAP3K2—lymph node—stomach cancer	0.000112	0.000936	CbGeAlD
Bosutinib—MAP3K7—lymph node—stomach cancer	0.000111	0.000927	CbGeAlD
Bosutinib—SRC—liver—stomach cancer	0.000111	0.000925	CbGeAlD
Bosutinib—CSF1R—endocrine gland—stomach cancer	0.00011	0.000921	CbGeAlD
Bosutinib—PTK2—lymph node—stomach cancer	0.00011	0.000916	CbGeAlD
Bosutinib—TBK1—lymph node—stomach cancer	0.00011	0.000916	CbGeAlD
Bosutinib—PDGFRB—bone marrow—stomach cancer	0.000109	0.000911	CbGeAlD
Bosutinib—IRAK1—lymph node—stomach cancer	0.000108	0.000898	CbGeAlD
Bosutinib—ABL1—lymphoid tissue—stomach cancer	0.000107	0.000892	CbGeAlD
Bosutinib—Renal failure—Methotrexate—stomach cancer	0.000106	0.000965	CcSEcCtD
Bosutinib—Neutropenia—Epirubicin—stomach cancer	0.000106	0.000964	CcSEcCtD
Bosutinib—RPS6KB1—lymph node—stomach cancer	0.000106	0.000881	CbGeAlD
Bosutinib—ABL1—digestive system—stomach cancer	0.000105	0.000881	CbGeAlD
Bosutinib—Upper respiratory tract infection—Epirubicin—stomach cancer	0.000105	0.000958	CcSEcCtD
Bosutinib—Ill-defined disorder—Capecitabine—stomach cancer	0.000105	0.000956	CcSEcCtD
Bosutinib—Urticaria—Fluorouracil—stomach cancer	0.000105	0.000956	CcSEcCtD
Bosutinib—FGR—lymph node—stomach cancer	0.000105	0.000876	CbGeAlD
Bosutinib—LCK—lymph node—stomach cancer	0.000105	0.000876	CbGeAlD
Bosutinib—Influenza—Doxorubicin—stomach cancer	0.000105	0.000954	CcSEcCtD
Bosutinib—Leukopenia—Docetaxel—stomach cancer	0.000105	0.000953	CcSEcCtD
Bosutinib—Anaemia—Capecitabine—stomach cancer	0.000105	0.000953	CcSEcCtD
Bosutinib—Body temperature increased—Fluorouracil—stomach cancer	0.000105	0.000952	CcSEcCtD
Bosutinib—AXL—lymph node—stomach cancer	0.000104	0.000873	CbGeAlD
Bosutinib—Malaise—Capecitabine—stomach cancer	0.000102	0.00093	CcSEcCtD
Bosutinib—Cough—Docetaxel—stomach cancer	0.000102	0.000929	CcSEcCtD
Bosutinib—Hepatobiliary disease—Methotrexate—stomach cancer	0.000102	0.000929	CcSEcCtD
Bosutinib—MAP2K5—liver—stomach cancer	0.000102	0.000851	CbGeAlD
Bosutinib—Pneumonia—Epirubicin—stomach cancer	0.000102	0.000924	CcSEcCtD
Bosutinib—Leukopenia—Capecitabine—stomach cancer	0.000101	0.000923	CcSEcCtD
Bosutinib—Infestation NOS—Epirubicin—stomach cancer	0.000101	0.000919	CcSEcCtD
Bosutinib—Infestation—Epirubicin—stomach cancer	0.000101	0.000919	CcSEcCtD
Bosutinib—Bronchitis—Doxorubicin—stomach cancer	0.000101	0.000917	CcSEcCtD
Bosutinib—Agranulocytosis—Methotrexate—stomach cancer	0.000101	0.000916	CcSEcCtD
Bosutinib—SLK—lymph node—stomach cancer	0.000101	0.00084	CbGeAlD
Bosutinib—EPHB4—lymph node—stomach cancer	9.99e-05	0.000834	CbGeAlD
Bosutinib—Myalgia—Docetaxel—stomach cancer	9.97e-05	0.000906	CcSEcCtD
Bosutinib—Arthralgia—Docetaxel—stomach cancer	9.97e-05	0.000906	CcSEcCtD
Bosutinib—Chest pain—Docetaxel—stomach cancer	9.97e-05	0.000906	CcSEcCtD
Bosutinib—Pancytopenia—Doxorubicin—stomach cancer	9.96e-05	0.000906	CcSEcCtD
Bosutinib—CSF1R—liver—stomach cancer	9.94e-05	0.00083	CbGeAlD
Bosutinib—Renal failure—Epirubicin—stomach cancer	9.93e-05	0.000903	CcSEcCtD
Bosutinib—Asthenia—Irinotecan—stomach cancer	9.92e-05	0.000902	CcSEcCtD
Bosutinib—CSK—Doxorubicin—Epirubicin—stomach cancer	9.9e-05	0.0278	CbGdCrCtD
Bosutinib—CSK—Daunorubicin—Epirubicin—stomach cancer	9.9e-05	0.0278	CbGdCrCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—stomach cancer	9.9e-05	0.0009	CcSEcCtD
Bosutinib—Cough—Capecitabine—stomach cancer	9.89e-05	0.000899	CcSEcCtD
Bosutinib—Neutropenia—Doxorubicin—stomach cancer	9.81e-05	0.000892	CcSEcCtD
Bosutinib—EPHA2—lymph node—stomach cancer	9.8e-05	0.000818	CbGeAlD
Bosutinib—PDGFRB—endocrine gland—stomach cancer	9.78e-05	0.000817	CbGeAlD
Bosutinib—FYN—lymph node—stomach cancer	9.78e-05	0.000817	CbGeAlD
Bosutinib—Upper respiratory tract infection—Doxorubicin—stomach cancer	9.75e-05	0.000886	CcSEcCtD
Bosutinib—ABL1—bone marrow—stomach cancer	9.72e-05	0.000812	CbGeAlD
Bosutinib—Hepatitis—Methotrexate—stomach cancer	9.69e-05	0.000881	CcSEcCtD
Bosutinib—Myalgia—Capecitabine—stomach cancer	9.65e-05	0.000878	CcSEcCtD
Bosutinib—Chest pain—Capecitabine—stomach cancer	9.65e-05	0.000878	CcSEcCtD
Bosutinib—Arthralgia—Capecitabine—stomach cancer	9.65e-05	0.000878	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—stomach cancer	9.59e-05	0.000871	CcSEcCtD
Bosutinib—Urinary tract disorder—Methotrexate—stomach cancer	9.57e-05	0.00087	CcSEcCtD
Bosutinib—Hepatobiliary disease—Epirubicin—stomach cancer	9.56e-05	0.000869	CcSEcCtD
Bosutinib—MAP3K3—lymph node—stomach cancer	9.56e-05	0.000798	CbGeAlD
Bosutinib—MAP4K5—lymph node—stomach cancer	9.56e-05	0.000798	CbGeAlD
Bosutinib—Anaphylactic shock—Docetaxel—stomach cancer	9.56e-05	0.000869	CcSEcCtD
Bosutinib—Oedema—Docetaxel—stomach cancer	9.56e-05	0.000869	CcSEcCtD
Bosutinib—Discomfort—Capecitabine—stomach cancer	9.54e-05	0.000867	CcSEcCtD
Bosutinib—Urethral disorder—Methotrexate—stomach cancer	9.5e-05	0.000864	CcSEcCtD
Bosutinib—Infection—Docetaxel—stomach cancer	9.49e-05	0.000863	CcSEcCtD
Bosutinib—Diarrhoea—Irinotecan—stomach cancer	9.46e-05	0.00086	CcSEcCtD
Bosutinib—Agranulocytosis—Epirubicin—stomach cancer	9.43e-05	0.000857	CcSEcCtD
Bosutinib—Pneumonia—Doxorubicin—stomach cancer	9.41e-05	0.000855	CcSEcCtD
Bosutinib—Nervous system disorder—Docetaxel—stomach cancer	9.37e-05	0.000852	CcSEcCtD
Bosutinib—Pruritus—Fluorouracil—stomach cancer	9.37e-05	0.000852	CcSEcCtD
Bosutinib—Thrombocytopenia—Docetaxel—stomach cancer	9.36e-05	0.000851	CcSEcCtD
Bosutinib—Infestation NOS—Doxorubicin—stomach cancer	9.35e-05	0.00085	CcSEcCtD
Bosutinib—Infestation—Doxorubicin—stomach cancer	9.35e-05	0.00085	CcSEcCtD
Bosutinib—Skin disorder—Docetaxel—stomach cancer	9.28e-05	0.000844	CcSEcCtD
Bosutinib—Oedema—Capecitabine—stomach cancer	9.25e-05	0.000841	CcSEcCtD
Bosutinib—Renal failure—Doxorubicin—stomach cancer	9.19e-05	0.000836	CcSEcCtD
Bosutinib—Infection—Capecitabine—stomach cancer	9.19e-05	0.000836	CcSEcCtD
Bosutinib—Erythema multiforme—Methotrexate—stomach cancer	9.17e-05	0.000833	CcSEcCtD
Bosutinib—CSK—Daunorubicin—Doxorubicin—stomach cancer	9.16e-05	0.0257	CbGdCrCtD
Bosutinib—CSK—Epirubicin—Doxorubicin—stomach cancer	9.16e-05	0.0257	CbGdCrCtD
Bosutinib—Dizziness—Irinotecan—stomach cancer	9.14e-05	0.000831	CcSEcCtD
Bosutinib—Nervous system disorder—Capecitabine—stomach cancer	9.07e-05	0.000825	CcSEcCtD
Bosutinib—Hepatitis—Epirubicin—stomach cancer	9.07e-05	0.000825	CcSEcCtD
Bosutinib—Diarrhoea—Fluorouracil—stomach cancer	9.06e-05	0.000824	CcSEcCtD
Bosutinib—Thrombocytopenia—Capecitabine—stomach cancer	9.06e-05	0.000824	CcSEcCtD
Bosutinib—Tinnitus—Methotrexate—stomach cancer	9.04e-05	0.000822	CcSEcCtD
Bosutinib—Cardiac disorder—Methotrexate—stomach cancer	9e-05	0.000818	CcSEcCtD
Bosutinib—Skin disorder—Capecitabine—stomach cancer	8.99e-05	0.000817	CcSEcCtD
Bosutinib—Urinary tract disorder—Epirubicin—stomach cancer	8.96e-05	0.000815	CcSEcCtD
Bosutinib—Oedema peripheral—Epirubicin—stomach cancer	8.94e-05	0.000813	CcSEcCtD
Bosutinib—Connective tissue disorder—Epirubicin—stomach cancer	8.92e-05	0.000811	CcSEcCtD
Bosutinib—Urethral disorder—Epirubicin—stomach cancer	8.89e-05	0.000809	CcSEcCtD
Bosutinib—ABCB1—blood vessel—stomach cancer	8.86e-05	0.00074	CbGeAlD
Bosutinib—Hepatobiliary disease—Doxorubicin—stomach cancer	8.84e-05	0.000804	CcSEcCtD
Bosutinib—YES1—lymph node—stomach cancer	8.83e-05	0.000737	CbGeAlD
Bosutinib—PDGFRB—liver—stomach cancer	8.82e-05	0.000736	CbGeAlD
Bosutinib—Vomiting—Irinotecan—stomach cancer	8.79e-05	0.000799	CcSEcCtD
Bosutinib—Immune system disorder—Methotrexate—stomach cancer	8.76e-05	0.000796	CcSEcCtD
Bosutinib—Dizziness—Fluorouracil—stomach cancer	8.76e-05	0.000796	CcSEcCtD
Bosutinib—STK10—lymph node—stomach cancer	8.75e-05	0.00073	CbGeAlD
Bosutinib—Mediastinal disorder—Methotrexate—stomach cancer	8.74e-05	0.000794	CcSEcCtD
Bosutinib—Agranulocytosis—Doxorubicin—stomach cancer	8.73e-05	0.000793	CcSEcCtD
Bosutinib—ABL1—endocrine gland—stomach cancer	8.72e-05	0.000728	CbGeAlD
Bosutinib—Rash—Irinotecan—stomach cancer	8.72e-05	0.000792	CcSEcCtD
Bosutinib—TAOK3—lymph node—stomach cancer	8.71e-05	0.000728	CbGeAlD
Bosutinib—Dermatitis—Irinotecan—stomach cancer	8.71e-05	0.000792	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Docetaxel—stomach cancer	8.71e-05	0.000792	CcSEcCtD
Bosutinib—Headache—Irinotecan—stomach cancer	8.66e-05	0.000787	CcSEcCtD
Bosutinib—Erythema multiforme—Epirubicin—stomach cancer	8.58e-05	0.00078	CcSEcCtD
Bosutinib—Dyspnoea—Docetaxel—stomach cancer	8.52e-05	0.000775	CcSEcCtD
Bosutinib—SRC—lymph node—stomach cancer	8.49e-05	0.000709	CbGeAlD
Bosutinib—Tinnitus—Epirubicin—stomach cancer	8.46e-05	0.000769	CcSEcCtD
Bosutinib—Malnutrition—Methotrexate—stomach cancer	8.44e-05	0.000767	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Capecitabine—stomach cancer	8.43e-05	0.000766	CcSEcCtD
Bosutinib—Cardiac disorder—Epirubicin—stomach cancer	8.42e-05	0.000766	CcSEcCtD
Bosutinib—Vomiting—Fluorouracil—stomach cancer	8.42e-05	0.000765	CcSEcCtD
Bosutinib—Hepatitis—Doxorubicin—stomach cancer	8.39e-05	0.000763	CcSEcCtD
Bosutinib—Rash—Fluorouracil—stomach cancer	8.35e-05	0.000759	CcSEcCtD
Bosutinib—Dermatitis—Fluorouracil—stomach cancer	8.34e-05	0.000758	CcSEcCtD
Bosutinib—Decreased appetite—Docetaxel—stomach cancer	8.31e-05	0.000755	CcSEcCtD
Bosutinib—Headache—Fluorouracil—stomach cancer	8.29e-05	0.000754	CcSEcCtD
Bosutinib—Urinary tract disorder—Doxorubicin—stomach cancer	8.29e-05	0.000754	CcSEcCtD
Bosutinib—Oedema peripheral—Doxorubicin—stomach cancer	8.27e-05	0.000752	CcSEcCtD
Bosutinib—Dysgeusia—Methotrexate—stomach cancer	8.26e-05	0.000751	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Docetaxel—stomach cancer	8.25e-05	0.00075	CcSEcCtD
Bosutinib—Connective tissue disorder—Doxorubicin—stomach cancer	8.25e-05	0.00075	CcSEcCtD
Bosutinib—Dyspnoea—Capecitabine—stomach cancer	8.25e-05	0.00075	CcSEcCtD
Bosutinib—Fatigue—Docetaxel—stomach cancer	8.24e-05	0.000749	CcSEcCtD
Bosutinib—Urethral disorder—Doxorubicin—stomach cancer	8.23e-05	0.000748	CcSEcCtD
Bosutinib—Nausea—Irinotecan—stomach cancer	8.21e-05	0.000747	CcSEcCtD
Bosutinib—Immune system disorder—Epirubicin—stomach cancer	8.2e-05	0.000745	CcSEcCtD
Bosutinib—Mediastinal disorder—Epirubicin—stomach cancer	8.18e-05	0.000743	CcSEcCtD
Bosutinib—Pain—Docetaxel—stomach cancer	8.17e-05	0.000743	CcSEcCtD
Bosutinib—Back pain—Methotrexate—stomach cancer	8.16e-05	0.000742	CcSEcCtD
Bosutinib—Decreased appetite—Capecitabine—stomach cancer	8.04e-05	0.000731	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Capecitabine—stomach cancer	7.99e-05	0.000726	CcSEcCtD
Bosutinib—Fatigue—Capecitabine—stomach cancer	7.98e-05	0.000725	CcSEcCtD
Bosutinib—Erythema multiforme—Doxorubicin—stomach cancer	7.94e-05	0.000722	CcSEcCtD
Bosutinib—Pain—Capecitabine—stomach cancer	7.91e-05	0.000719	CcSEcCtD
Bosutinib—Malnutrition—Epirubicin—stomach cancer	7.9e-05	0.000718	CcSEcCtD
Bosutinib—Feeling abnormal—Docetaxel—stomach cancer	7.88e-05	0.000716	CcSEcCtD
Bosutinib—Nausea—Fluorouracil—stomach cancer	7.86e-05	0.000715	CcSEcCtD
Bosutinib—ABL1—liver—stomach cancer	7.86e-05	0.000656	CbGeAlD
Bosutinib—Ill-defined disorder—Methotrexate—stomach cancer	7.83e-05	0.000712	CcSEcCtD
Bosutinib—Tinnitus—Doxorubicin—stomach cancer	7.83e-05	0.000712	CcSEcCtD
Bosutinib—Gastrointestinal pain—Docetaxel—stomach cancer	7.81e-05	0.00071	CcSEcCtD
Bosutinib—MAP2K5—lymph node—stomach cancer	7.81e-05	0.000652	CbGeAlD
Bosutinib—Anaemia—Methotrexate—stomach cancer	7.8e-05	0.000709	CcSEcCtD
Bosutinib—Cardiac disorder—Doxorubicin—stomach cancer	7.79e-05	0.000708	CcSEcCtD
Bosutinib—Dysgeusia—Epirubicin—stomach cancer	7.73e-05	0.000703	CcSEcCtD
Bosutinib—Back pain—Epirubicin—stomach cancer	7.64e-05	0.000695	CcSEcCtD
Bosutinib—Feeling abnormal—Capecitabine—stomach cancer	7.62e-05	0.000693	CcSEcCtD
Bosutinib—CSF1R—lymph node—stomach cancer	7.62e-05	0.000637	CbGeAlD
Bosutinib—Malaise—Methotrexate—stomach cancer	7.61e-05	0.000692	CcSEcCtD
Bosutinib—Immune system disorder—Doxorubicin—stomach cancer	7.58e-05	0.000689	CcSEcCtD
Bosutinib—Gastrointestinal pain—Capecitabine—stomach cancer	7.57e-05	0.000688	CcSEcCtD
Bosutinib—Mediastinal disorder—Doxorubicin—stomach cancer	7.57e-05	0.000688	CcSEcCtD
Bosutinib—Body temperature increased—Docetaxel—stomach cancer	7.55e-05	0.000687	CcSEcCtD
Bosutinib—Abdominal pain—Docetaxel—stomach cancer	7.55e-05	0.000687	CcSEcCtD
Bosutinib—Leukopenia—Methotrexate—stomach cancer	7.55e-05	0.000687	CcSEcCtD
Bosutinib—Cough—Methotrexate—stomach cancer	7.36e-05	0.00067	CcSEcCtD
Bosutinib—Urticaria—Capecitabine—stomach cancer	7.35e-05	0.000668	CcSEcCtD
Bosutinib—Ill-defined disorder—Epirubicin—stomach cancer	7.33e-05	0.000666	CcSEcCtD
Bosutinib—Abdominal pain—Capecitabine—stomach cancer	7.31e-05	0.000665	CcSEcCtD
Bosutinib—Body temperature increased—Capecitabine—stomach cancer	7.31e-05	0.000665	CcSEcCtD
Bosutinib—Malnutrition—Doxorubicin—stomach cancer	7.31e-05	0.000664	CcSEcCtD
Bosutinib—Anaemia—Epirubicin—stomach cancer	7.3e-05	0.000664	CcSEcCtD
Bosutinib—CHEK2—Doxorubicin—Epirubicin—stomach cancer	7.25e-05	0.0204	CbGdCrCtD
Bosutinib—Arthralgia—Methotrexate—stomach cancer	7.19e-05	0.000653	CcSEcCtD
Bosutinib—Myalgia—Methotrexate—stomach cancer	7.19e-05	0.000653	CcSEcCtD
Bosutinib—Chest pain—Methotrexate—stomach cancer	7.19e-05	0.000653	CcSEcCtD
Bosutinib—Dysgeusia—Doxorubicin—stomach cancer	7.16e-05	0.000651	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	7.14e-05	0.000649	CcSEcCtD
Bosutinib—Malaise—Epirubicin—stomach cancer	7.12e-05	0.000648	CcSEcCtD
Bosutinib—Discomfort—Methotrexate—stomach cancer	7.1e-05	0.000645	CcSEcCtD
Bosutinib—Leukopenia—Epirubicin—stomach cancer	7.07e-05	0.000643	CcSEcCtD
Bosutinib—Back pain—Doxorubicin—stomach cancer	7.07e-05	0.000643	CcSEcCtD
Bosutinib—ABL1—Idarubicin—Epirubicin—stomach cancer	6.92e-05	0.0194	CbGdCrCtD
Bosutinib—ABL1—Daunorubicin—Epirubicin—stomach cancer	6.92e-05	0.0194	CbGdCrCtD
Bosutinib—ABL1—Doxorubicin—Epirubicin—stomach cancer	6.92e-05	0.0194	CbGdCrCtD
Bosutinib—Cough—Epirubicin—stomach cancer	6.89e-05	0.000627	CcSEcCtD
Bosutinib—Anaphylactic shock—Methotrexate—stomach cancer	6.89e-05	0.000626	CcSEcCtD
Bosutinib—Asthenia—Docetaxel—stomach cancer	6.86e-05	0.000623	CcSEcCtD
Bosutinib—Infection—Methotrexate—stomach cancer	6.84e-05	0.000622	CcSEcCtD
Bosutinib—Ill-defined disorder—Doxorubicin—stomach cancer	6.78e-05	0.000616	CcSEcCtD
Bosutinib—Pruritus—Docetaxel—stomach cancer	6.76e-05	0.000615	CcSEcCtD
Bosutinib—PDGFRB—lymph node—stomach cancer	6.76e-05	0.000565	CbGeAlD
Bosutinib—Nervous system disorder—Methotrexate—stomach cancer	6.75e-05	0.000614	CcSEcCtD
Bosutinib—Anaemia—Doxorubicin—stomach cancer	6.75e-05	0.000614	CcSEcCtD
Bosutinib—Thrombocytopenia—Methotrexate—stomach cancer	6.74e-05	0.000613	CcSEcCtD
Bosutinib—Arthralgia—Epirubicin—stomach cancer	6.72e-05	0.000611	CcSEcCtD
Bosutinib—Myalgia—Epirubicin—stomach cancer	6.72e-05	0.000611	CcSEcCtD
Bosutinib—Chest pain—Epirubicin—stomach cancer	6.72e-05	0.000611	CcSEcCtD
Bosutinib—CHEK2—Epirubicin—Doxorubicin—stomach cancer	6.71e-05	0.0188	CbGdCrCtD
Bosutinib—Skin disorder—Methotrexate—stomach cancer	6.69e-05	0.000608	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	6.68e-05	0.000607	CcSEcCtD
Bosutinib—CYP3A4—hematopoietic system—stomach cancer	6.66e-05	0.000556	CbGeAlD
Bosutinib—Discomfort—Epirubicin—stomach cancer	6.64e-05	0.000604	CcSEcCtD
Bosutinib—Asthenia—Capecitabine—stomach cancer	6.64e-05	0.000604	CcSEcCtD
Bosutinib—Malaise—Doxorubicin—stomach cancer	6.59e-05	0.000599	CcSEcCtD
Bosutinib—Pruritus—Capecitabine—stomach cancer	6.55e-05	0.000595	CcSEcCtD
Bosutinib—Leukopenia—Doxorubicin—stomach cancer	6.54e-05	0.000595	CcSEcCtD
Bosutinib—Diarrhoea—Docetaxel—stomach cancer	6.54e-05	0.000594	CcSEcCtD
Bosutinib—Oedema—Epirubicin—stomach cancer	6.45e-05	0.000586	CcSEcCtD
Bosutinib—Anaphylactic shock—Epirubicin—stomach cancer	6.45e-05	0.000586	CcSEcCtD
Bosutinib—Infection—Epirubicin—stomach cancer	6.4e-05	0.000582	CcSEcCtD
Bosutinib—ABL1—Idarubicin—Doxorubicin—stomach cancer	6.4e-05	0.018	CbGdCrCtD
Bosutinib—ABL1—Epirubicin—Doxorubicin—stomach cancer	6.4e-05	0.018	CbGdCrCtD
Bosutinib—ABL1—Daunorubicin—Doxorubicin—stomach cancer	6.4e-05	0.018	CbGdCrCtD
Bosutinib—Cough—Doxorubicin—stomach cancer	6.38e-05	0.00058	CcSEcCtD
Bosutinib—Diarrhoea—Capecitabine—stomach cancer	6.33e-05	0.000576	CcSEcCtD
Bosutinib—Nervous system disorder—Epirubicin—stomach cancer	6.32e-05	0.000575	CcSEcCtD
Bosutinib—Dizziness—Docetaxel—stomach cancer	6.32e-05	0.000575	CcSEcCtD
Bosutinib—Thrombocytopenia—Epirubicin—stomach cancer	6.31e-05	0.000574	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Methotrexate—stomach cancer	6.28e-05	0.000571	CcSEcCtD
Bosutinib—Skin disorder—Epirubicin—stomach cancer	6.26e-05	0.000569	CcSEcCtD
Bosutinib—Chest pain—Doxorubicin—stomach cancer	6.22e-05	0.000566	CcSEcCtD
Bosutinib—Arthralgia—Doxorubicin—stomach cancer	6.22e-05	0.000566	CcSEcCtD
Bosutinib—Myalgia—Doxorubicin—stomach cancer	6.22e-05	0.000566	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	6.18e-05	0.000562	CcSEcCtD
Bosutinib—Discomfort—Doxorubicin—stomach cancer	6.15e-05	0.000559	CcSEcCtD
Bosutinib—Dyspnoea—Methotrexate—stomach cancer	6.14e-05	0.000558	CcSEcCtD
Bosutinib—Dizziness—Capecitabine—stomach cancer	6.12e-05	0.000556	CcSEcCtD
Bosutinib—Vomiting—Docetaxel—stomach cancer	6.08e-05	0.000552	CcSEcCtD
Bosutinib—ABL1—lymph node—stomach cancer	6.03e-05	0.000503	CbGeAlD
Bosutinib—Rash—Docetaxel—stomach cancer	6.03e-05	0.000548	CcSEcCtD
Bosutinib—Dermatitis—Docetaxel—stomach cancer	6.02e-05	0.000547	CcSEcCtD
Bosutinib—Decreased appetite—Methotrexate—stomach cancer	5.99e-05	0.000544	CcSEcCtD
Bosutinib—Headache—Docetaxel—stomach cancer	5.99e-05	0.000544	CcSEcCtD
Bosutinib—Anaphylactic shock—Doxorubicin—stomach cancer	5.96e-05	0.000542	CcSEcCtD
Bosutinib—Oedema—Doxorubicin—stomach cancer	5.96e-05	0.000542	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Methotrexate—stomach cancer	5.95e-05	0.000541	CcSEcCtD
Bosutinib—Fatigue—Methotrexate—stomach cancer	5.94e-05	0.00054	CcSEcCtD
Bosutinib—Infection—Doxorubicin—stomach cancer	5.93e-05	0.000539	CcSEcCtD
Bosutinib—Pain—Methotrexate—stomach cancer	5.89e-05	0.000536	CcSEcCtD
Bosutinib—Vomiting—Capecitabine—stomach cancer	5.88e-05	0.000535	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Epirubicin—stomach cancer	5.87e-05	0.000534	CcSEcCtD
Bosutinib—Nervous system disorder—Doxorubicin—stomach cancer	5.85e-05	0.000532	CcSEcCtD
Bosutinib—Thrombocytopenia—Doxorubicin—stomach cancer	5.84e-05	0.000531	CcSEcCtD
Bosutinib—Rash—Capecitabine—stomach cancer	5.83e-05	0.00053	CcSEcCtD
Bosutinib—Dermatitis—Capecitabine—stomach cancer	5.83e-05	0.00053	CcSEcCtD
Bosutinib—Headache—Capecitabine—stomach cancer	5.8e-05	0.000527	CcSEcCtD
Bosutinib—Skin disorder—Doxorubicin—stomach cancer	5.79e-05	0.000527	CcSEcCtD
Bosutinib—Dyspnoea—Epirubicin—stomach cancer	5.75e-05	0.000522	CcSEcCtD
Bosutinib—Nausea—Docetaxel—stomach cancer	5.68e-05	0.000516	CcSEcCtD
Bosutinib—Feeling abnormal—Methotrexate—stomach cancer	5.68e-05	0.000516	CcSEcCtD
Bosutinib—Gastrointestinal pain—Methotrexate—stomach cancer	5.63e-05	0.000512	CcSEcCtD
Bosutinib—Decreased appetite—Epirubicin—stomach cancer	5.6e-05	0.000509	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Epirubicin—stomach cancer	5.56e-05	0.000506	CcSEcCtD
Bosutinib—Fatigue—Epirubicin—stomach cancer	5.56e-05	0.000505	CcSEcCtD
Bosutinib—Pain—Epirubicin—stomach cancer	5.51e-05	0.000501	CcSEcCtD
Bosutinib—Nausea—Capecitabine—stomach cancer	5.5e-05	0.0005	CcSEcCtD
Bosutinib—Urticaria—Methotrexate—stomach cancer	5.47e-05	0.000497	CcSEcCtD
Bosutinib—Abdominal pain—Methotrexate—stomach cancer	5.44e-05	0.000495	CcSEcCtD
Bosutinib—Body temperature increased—Methotrexate—stomach cancer	5.44e-05	0.000495	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Doxorubicin—stomach cancer	5.43e-05	0.000494	CcSEcCtD
Bosutinib—Dyspnoea—Doxorubicin—stomach cancer	5.32e-05	0.000483	CcSEcCtD
Bosutinib—Feeling abnormal—Epirubicin—stomach cancer	5.31e-05	0.000483	CcSEcCtD
Bosutinib—Gastrointestinal pain—Epirubicin—stomach cancer	5.27e-05	0.000479	CcSEcCtD
Bosutinib—Decreased appetite—Doxorubicin—stomach cancer	5.18e-05	0.000471	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Doxorubicin—stomach cancer	5.15e-05	0.000468	CcSEcCtD
Bosutinib—Fatigue—Doxorubicin—stomach cancer	5.14e-05	0.000468	CcSEcCtD
Bosutinib—Urticaria—Epirubicin—stomach cancer	5.12e-05	0.000466	CcSEcCtD
Bosutinib—Pain—Doxorubicin—stomach cancer	5.1e-05	0.000464	CcSEcCtD
Bosutinib—Abdominal pain—Epirubicin—stomach cancer	5.1e-05	0.000463	CcSEcCtD
Bosutinib—Body temperature increased—Epirubicin—stomach cancer	5.1e-05	0.000463	CcSEcCtD
Bosutinib—Asthenia—Methotrexate—stomach cancer	4.94e-05	0.000449	CcSEcCtD
Bosutinib—Feeling abnormal—Doxorubicin—stomach cancer	4.91e-05	0.000447	CcSEcCtD
Bosutinib—Gastrointestinal pain—Doxorubicin—stomach cancer	4.88e-05	0.000443	CcSEcCtD
Bosutinib—Pruritus—Methotrexate—stomach cancer	4.87e-05	0.000443	CcSEcCtD
Bosutinib—Urticaria—Doxorubicin—stomach cancer	4.74e-05	0.000431	CcSEcCtD
Bosutinib—ABCB1—hematopoietic system—stomach cancer	4.72e-05	0.000394	CbGeAlD
Bosutinib—Abdominal pain—Doxorubicin—stomach cancer	4.71e-05	0.000429	CcSEcCtD
Bosutinib—Body temperature increased—Doxorubicin—stomach cancer	4.71e-05	0.000429	CcSEcCtD
Bosutinib—Diarrhoea—Methotrexate—stomach cancer	4.71e-05	0.000428	CcSEcCtD
Bosutinib—CYP3A4—digestive system—stomach cancer	4.63e-05	0.000387	CbGeAlD
Bosutinib—Asthenia—Epirubicin—stomach cancer	4.62e-05	0.00042	CcSEcCtD
Bosutinib—Pruritus—Epirubicin—stomach cancer	4.56e-05	0.000415	CcSEcCtD
Bosutinib—Dizziness—Methotrexate—stomach cancer	4.55e-05	0.000414	CcSEcCtD
Bosutinib—Diarrhoea—Epirubicin—stomach cancer	4.41e-05	0.000401	CcSEcCtD
Bosutinib—Vomiting—Methotrexate—stomach cancer	4.38e-05	0.000398	CcSEcCtD
Bosutinib—Rash—Methotrexate—stomach cancer	4.34e-05	0.000395	CcSEcCtD
Bosutinib—Dermatitis—Methotrexate—stomach cancer	4.34e-05	0.000394	CcSEcCtD
Bosutinib—Headache—Methotrexate—stomach cancer	4.32e-05	0.000392	CcSEcCtD
Bosutinib—ABCB1—epithelium—stomach cancer	4.31e-05	0.00036	CbGeAlD
Bosutinib—Asthenia—Doxorubicin—stomach cancer	4.28e-05	0.000389	CcSEcCtD
Bosutinib—Dizziness—Epirubicin—stomach cancer	4.26e-05	0.000388	CcSEcCtD
Bosutinib—Pruritus—Doxorubicin—stomach cancer	4.22e-05	0.000384	CcSEcCtD
Bosutinib—Vomiting—Epirubicin—stomach cancer	4.1e-05	0.000373	CcSEcCtD
Bosutinib—Nausea—Methotrexate—stomach cancer	4.09e-05	0.000372	CcSEcCtD
Bosutinib—Diarrhoea—Doxorubicin—stomach cancer	4.08e-05	0.000371	CcSEcCtD
Bosutinib—Rash—Epirubicin—stomach cancer	4.06e-05	0.00037	CcSEcCtD
Bosutinib—Dermatitis—Epirubicin—stomach cancer	4.06e-05	0.000369	CcSEcCtD
Bosutinib—Headache—Epirubicin—stomach cancer	4.04e-05	0.000367	CcSEcCtD
Bosutinib—Dizziness—Doxorubicin—stomach cancer	3.94e-05	0.000359	CcSEcCtD
Bosutinib—ABCB1—pancreas—stomach cancer	3.84e-05	0.000321	CbGeAlD
Bosutinib—CYP3A4—endocrine gland—stomach cancer	3.83e-05	0.00032	CbGeAlD
Bosutinib—Nausea—Epirubicin—stomach cancer	3.83e-05	0.000348	CcSEcCtD
Bosutinib—Vomiting—Doxorubicin—stomach cancer	3.79e-05	0.000345	CcSEcCtD
Bosutinib—Rash—Doxorubicin—stomach cancer	3.76e-05	0.000342	CcSEcCtD
Bosutinib—Dermatitis—Doxorubicin—stomach cancer	3.76e-05	0.000342	CcSEcCtD
Bosutinib—Headache—Doxorubicin—stomach cancer	3.74e-05	0.00034	CcSEcCtD
Bosutinib—Nausea—Doxorubicin—stomach cancer	3.54e-05	0.000322	CcSEcCtD
Bosutinib—CYP3A4—liver—stomach cancer	3.45e-05	0.000288	CbGeAlD
Bosutinib—ABCB1—lymphoid tissue—stomach cancer	3.32e-05	0.000277	CbGeAlD
Bosutinib—ABCB1—digestive system—stomach cancer	3.28e-05	0.000274	CbGeAlD
Bosutinib—ABCB1—bone marrow—stomach cancer	3.02e-05	0.000253	CbGeAlD
Bosutinib—ABCB1—endocrine gland—stomach cancer	2.71e-05	0.000226	CbGeAlD
Bosutinib—ABCB1—liver—stomach cancer	2.44e-05	0.000204	CbGeAlD
Bosutinib—ABCB1—lymph node—stomach cancer	1.87e-05	0.000156	CbGeAlD
Bosutinib—ROCK1—Signaling Pathways—IL6—stomach cancer	4.21e-07	2.07e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NOS3—stomach cancer	4.21e-07	2.07e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MMP9—stomach cancer	4.21e-07	2.07e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MAPK8—stomach cancer	4.19e-07	2.06e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CDKN1A—stomach cancer	4.19e-07	2.06e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MAPK3—stomach cancer	4.19e-07	2.06e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CCND1—stomach cancer	4.18e-07	2.05e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—JUN—stomach cancer	4.17e-07	2.05e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL6R—stomach cancer	4.17e-07	2.05e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—PIK3CA—stomach cancer	4.16e-07	2.04e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CCND1—stomach cancer	4.16e-07	2.04e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—JUN—stomach cancer	4.15e-07	2.04e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—IL6—stomach cancer	4.14e-07	2.03e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—KRAS—stomach cancer	4.14e-07	2.03e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GSTT1—stomach cancer	4.14e-07	2.03e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—HRAS—stomach cancer	4.14e-07	2.03e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—MYC—stomach cancer	4.14e-07	2.03e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MMP9—stomach cancer	4.12e-07	2.02e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—HRAS—stomach cancer	4.12e-07	2.02e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—STAT3—stomach cancer	4.11e-07	2.02e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CDKN1A—stomach cancer	4.11e-07	2.02e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—MAPK3—stomach cancer	4.1e-07	2.01e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MAPK8—stomach cancer	4.09e-07	2.01e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP2A6—stomach cancer	4.09e-07	2.01e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—ERBB2—stomach cancer	4.09e-07	2.01e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—HRAS—stomach cancer	4.09e-07	2.01e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MYC—stomach cancer	4.08e-07	2e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—HRAS—stomach cancer	4.07e-07	2e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—PIK3CA—stomach cancer	4.06e-07	1.99e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MMP9—stomach cancer	4.06e-07	1.99e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—IL6—stomach cancer	4.06e-07	1.99e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—IL6—stomach cancer	4.06e-07	1.99e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—HRAS—stomach cancer	4.05e-07	1.99e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—MAPK1—stomach cancer	4.05e-07	1.99e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—IL6—stomach cancer	4.04e-07	1.98e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CDKN1A—stomach cancer	4.04e-07	1.98e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—PIK3CA—stomach cancer	4.04e-07	1.98e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MMP9—stomach cancer	4.04e-07	1.98e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—ERCC2—stomach cancer	4.02e-07	1.97e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CDKN1A—stomach cancer	4.02e-07	1.97e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MAPK8—stomach cancer	4.01e-07	1.97e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—KRAS—stomach cancer	4e-07	1.96e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—HRAS—stomach cancer	4e-07	1.96e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MAPK1—stomach cancer	3.99e-07	1.96e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—EGFR—stomach cancer	3.99e-07	1.96e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—KRAS—stomach cancer	3.99e-07	1.96e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—MYC—stomach cancer	3.99e-07	1.96e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AKR1C3—stomach cancer	3.98e-07	1.95e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—IL6—stomach cancer	3.96e-07	1.94e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MAPK8—stomach cancer	3.95e-07	1.94e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IL6—stomach cancer	3.94e-07	1.93e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—ERBB2—stomach cancer	3.94e-07	1.93e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—PIK3CA—stomach cancer	3.93e-07	1.93e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—MAPK3—stomach cancer	3.93e-07	1.93e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MAPK8—stomach cancer	3.92e-07	1.93e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—IL6—stomach cancer	3.91e-07	1.92e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—SERPINE1—stomach cancer	3.9e-07	1.92e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—HRAS—stomach cancer	3.9e-07	1.91e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—MAPK1—stomach cancer	3.9e-07	1.91e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—EGFR—stomach cancer	3.9e-07	1.91e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL6—stomach cancer	3.9e-07	1.91e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ENO1—stomach cancer	3.88e-07	1.9e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL6—stomach cancer	3.88e-07	1.9e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—PIK3CA—stomach cancer	3.88e-07	1.9e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CXCL8—stomach cancer	3.88e-07	1.9e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—VEGFA—stomach cancer	3.87e-07	1.9e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—HRAS—stomach cancer	3.85e-07	1.89e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—STAT3—stomach cancer	3.84e-07	1.88e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—IL6—stomach cancer	3.83e-07	1.88e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—KRAS—stomach cancer	3.82e-07	1.88e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TP53—stomach cancer	3.8e-07	1.87e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—PIK3CA—stomach cancer	3.8e-07	1.87e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—STAT3—stomach cancer	3.8e-07	1.86e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CDKN1B—stomach cancer	3.78e-07	1.86e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—MTHFR—stomach cancer	3.78e-07	1.86e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—VEGFA—stomach cancer	3.78e-07	1.86e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—KRAS—stomach cancer	3.77e-07	1.85e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—RHOA—stomach cancer	3.77e-07	1.85e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—HRAS—stomach cancer	3.76e-07	1.85e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—stomach cancer	3.75e-07	1.84e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—STAT3—stomach cancer	3.74e-07	1.84e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—HRAS—stomach cancer	3.74e-07	1.84e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—MAPK1—stomach cancer	3.74e-07	1.84e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—EGFR—stomach cancer	3.74e-07	1.83e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CXCL8—stomach cancer	3.73e-07	1.83e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—IL6—stomach cancer	3.73e-07	1.83e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NOS3—stomach cancer	3.73e-07	1.83e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—VEGFA—stomach cancer	3.7e-07	1.82e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—IL6—stomach cancer	3.69e-07	1.81e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—KRAS—stomach cancer	3.68e-07	1.81e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—PIK3CA—stomach cancer	3.68e-07	1.8e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—PIK3CA—stomach cancer	3.66e-07	1.8e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—STAT3—stomach cancer	3.66e-07	1.8e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MAPK3—stomach cancer	3.66e-07	1.8e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CDKN1B—stomach cancer	3.65e-07	1.79e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—VEGFA—stomach cancer	3.64e-07	1.79e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—HRAS—stomach cancer	3.64e-07	1.79e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MAPK3—stomach cancer	3.63e-07	1.78e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—VEGFA—stomach cancer	3.62e-07	1.78e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CCND1—stomach cancer	3.61e-07	1.77e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—STAT3—stomach cancer	3.61e-07	1.77e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—JUN—stomach cancer	3.6e-07	1.77e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—IL6—stomach cancer	3.6e-07	1.77e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—STAT3—stomach cancer	3.59e-07	1.76e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—HRAS—stomach cancer	3.59e-07	1.76e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—IL6—stomach cancer	3.58e-07	1.76e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MAPK3—stomach cancer	3.58e-07	1.76e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MYC—stomach cancer	3.56e-07	1.75e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—stomach cancer	3.56e-07	1.75e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—KRAS—stomach cancer	3.53e-07	1.73e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MYC—stomach cancer	3.53e-07	1.73e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—HRAS—stomach cancer	3.52e-07	1.73e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—PIK3CA—stomach cancer	3.51e-07	1.72e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MMP9—stomach cancer	3.51e-07	1.72e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MAPK3—stomach cancer	3.5e-07	1.72e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CDKN1A—stomach cancer	3.49e-07	1.71e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CAV1—stomach cancer	3.49e-07	1.71e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—ERBB2—stomach cancer	3.49e-07	1.71e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MAPK1—stomach cancer	3.49e-07	1.71e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—EGFR—stomach cancer	3.49e-07	1.71e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—IL6—stomach cancer	3.48e-07	1.71e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—APOA1—stomach cancer	3.48e-07	1.71e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CCND1—stomach cancer	3.48e-07	1.71e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MYC—stomach cancer	3.48e-07	1.71e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—JUN—stomach cancer	3.47e-07	1.7e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—PIK3CA—stomach cancer	3.46e-07	1.7e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MAPK1—stomach cancer	3.45e-07	1.69e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—EGFR—stomach cancer	3.45e-07	1.69e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MAPK3—stomach cancer	3.45e-07	1.69e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CD44—stomach cancer	3.44e-07	1.69e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IL6—stomach cancer	3.43e-07	1.69e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MAPK3—stomach cancer	3.43e-07	1.68e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MAPK8—stomach cancer	3.41e-07	1.67e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MYC—stomach cancer	3.4e-07	1.67e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MAPK1—stomach cancer	3.4e-07	1.67e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—HRAS—stomach cancer	3.4e-07	1.67e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—EGFR—stomach cancer	3.4e-07	1.67e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—HRAS—stomach cancer	3.39e-07	1.66e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—PIK3CA—stomach cancer	3.38e-07	1.66e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MMP9—stomach cancer	3.38e-07	1.66e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL6—stomach cancer	3.37e-07	1.65e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CDKN1A—stomach cancer	3.37e-07	1.65e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MYC—stomach cancer	3.35e-07	1.65e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—stomach cancer	3.35e-07	1.64e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MYC—stomach cancer	3.33e-07	1.64e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MAPK1—stomach cancer	3.33e-07	1.64e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EGFR—stomach cancer	3.33e-07	1.63e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CXCL8—stomach cancer	3.31e-07	1.62e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—KRAS—stomach cancer	3.29e-07	1.62e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MAPK8—stomach cancer	3.29e-07	1.61e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MAPK1—stomach cancer	3.28e-07	1.61e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EGFR—stomach cancer	3.28e-07	1.61e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MAPK1—stomach cancer	3.26e-07	1.6e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EGFR—stomach cancer	3.26e-07	1.6e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—KRAS—stomach cancer	3.26e-07	1.6e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IL6—stomach cancer	3.26e-07	1.6e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—HRAS—stomach cancer	3.25e-07	1.59e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL6—stomach cancer	3.24e-07	1.59e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—PIK3CA—stomach cancer	3.24e-07	1.59e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CDKN1B—stomach cancer	3.23e-07	1.58e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—KRAS—stomach cancer	3.21e-07	1.58e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—HRAS—stomach cancer	3.2e-07	1.57e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—VEGFA—stomach cancer	3.15e-07	1.55e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—KRAS—stomach cancer	3.15e-07	1.54e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—HRAS—stomach cancer	3.13e-07	1.54e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—STAT3—stomach cancer	3.12e-07	1.53e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—IL6—stomach cancer	3.11e-07	1.53e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—KRAS—stomach cancer	3.1e-07	1.52e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—KRAS—stomach cancer	3.08e-07	1.51e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCND1—stomach cancer	3.08e-07	1.51e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—JUN—stomach cancer	3.07e-07	1.51e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PPARG—stomach cancer	3.07e-07	1.51e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IL6—stomach cancer	3.07e-07	1.5e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—VEGFA—stomach cancer	3.03e-07	1.49e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—PIK3CA—stomach cancer	3.03e-07	1.49e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—STAT3—stomach cancer	3e-07	1.47e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—HRAS—stomach cancer	3e-07	1.47e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—IL6—stomach cancer	3e-07	1.47e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—PIK3CA—stomach cancer	2.99e-07	1.47e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MMP9—stomach cancer	2.99e-07	1.47e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CDKN1A—stomach cancer	2.98e-07	1.46e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MAPK3—stomach cancer	2.98e-07	1.46e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—PIK3CA—stomach cancer	2.95e-07	1.45e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—stomach cancer	2.93e-07	1.44e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PPP2R1A—stomach cancer	2.92e-07	1.44e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MAPK8—stomach cancer	2.91e-07	1.43e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MYC—stomach cancer	2.9e-07	1.42e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—PIK3CA—stomach cancer	2.89e-07	1.42e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL6—stomach cancer	2.87e-07	1.41e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MAPK3—stomach cancer	2.87e-07	1.41e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GSTP1—stomach cancer	2.87e-07	1.41e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—stomach cancer	2.86e-07	1.4e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—PIK3CA—stomach cancer	2.85e-07	1.4e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MAPK1—stomach cancer	2.83e-07	1.39e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—PIK3CA—stomach cancer	2.83e-07	1.39e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—HMOX1—stomach cancer	2.83e-07	1.39e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—HRAS—stomach cancer	2.8e-07	1.37e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—stomach cancer	2.8e-07	1.37e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MYC—stomach cancer	2.79e-07	1.37e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—HRAS—stomach cancer	2.77e-07	1.36e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—ALB—stomach cancer	2.76e-07	1.35e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—stomach cancer	2.75e-07	1.35e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—stomach cancer	2.74e-07	1.34e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—HRAS—stomach cancer	2.73e-07	1.34e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MAPK1—stomach cancer	2.73e-07	1.34e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EGFR—stomach cancer	2.73e-07	1.34e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—VEGFA—stomach cancer	2.69e-07	1.32e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL6—stomach cancer	2.68e-07	1.32e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—KRAS—stomach cancer	2.68e-07	1.31e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—HRAS—stomach cancer	2.67e-07	1.31e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—TYMS—stomach cancer	2.67e-07	1.31e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—STAT3—stomach cancer	2.66e-07	1.31e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—IL6—stomach cancer	2.65e-07	1.3e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—NOS3—stomach cancer	2.64e-07	1.29e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GSTM1—stomach cancer	2.64e-07	1.29e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—HRAS—stomach cancer	2.63e-07	1.29e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—HRAS—stomach cancer	2.62e-07	1.29e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL6—stomach cancer	2.61e-07	1.28e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—KRAS—stomach cancer	2.58e-07	1.27e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL6—stomach cancer	2.56e-07	1.26e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MAPK3—stomach cancer	2.54e-07	1.25e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL6—stomach cancer	2.52e-07	1.24e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL6—stomach cancer	2.51e-07	1.23e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ERCC2—stomach cancer	2.48e-07	1.22e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MYC—stomach cancer	2.47e-07	1.21e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PIK3CA—stomach cancer	2.46e-07	1.21e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MAPK1—stomach cancer	2.42e-07	1.19e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EGFR—stomach cancer	2.42e-07	1.19e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTGS2—stomach cancer	2.41e-07	1.18e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—stomach cancer	2.38e-07	1.17e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PIK3CA—stomach cancer	2.37e-07	1.16e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—MTHFR—stomach cancer	2.33e-07	1.14e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—stomach cancer	2.29e-07	1.13e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—KRAS—stomach cancer	2.28e-07	1.12e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—HRAS—stomach cancer	2.27e-07	1.12e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—HRAS—stomach cancer	2.19e-07	1.08e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL6—stomach cancer	2.18e-07	1.07e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CAV1—stomach cancer	2.15e-07	1.05e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—APOA1—stomach cancer	2.14e-07	1.05e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL6—stomach cancer	2.1e-07	1.03e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3CA—stomach cancer	2.1e-07	1.03e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—stomach cancer	2.03e-07	9.96e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—HRAS—stomach cancer	1.94e-07	9.53e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PPARG—stomach cancer	1.89e-07	9.27e-07	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL6—stomach cancer	1.86e-07	9.12e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ALB—stomach cancer	1.7e-07	8.34e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NOS3—stomach cancer	1.62e-07	7.98e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTGS2—stomach cancer	1.49e-07	7.3e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3CA—stomach cancer	1.48e-07	7.28e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3CA—stomach cancer	9.14e-08	4.49e-07	CbGpPWpGaD
